Skip to content
The Policy VaultThe Policy Vault

Phyrago — CareFirst (Caremark)

Myeloid/Lymphoid Neoplasms with Eosinophilia and ABL1 rearrangement

Initial criteria

  • Diagnosis in chronic or blast phase with ABL1 rearrangement

Reauthorization criteria

  • No evidence of unacceptable toxicity or disease progression while on current regimen

Approval duration

12 months